Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show

02 Nov 2026 0 comments

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

Source: NeurologyLive Published 02 Nov 2026 Imported 02 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment